GluN2B/N-methyl-D-aspartate Receptor Antagonists: Advances in Design, Synthesis, and Pharmacological Evaluation Studies

Author(s): Vinod Ugale*, Ashish Dhote, Rushikesh Narwade, Saurabh Khadse, P. Narayana Reddy, Atul Shirkhedkar

Journal Name: CNS & Neurological Disorders - Drug Targets
Formerly Current Drug Targets - CNS & Neurological Disorders

Volume 20 , Issue 9 , 2021

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Selective GluN2B/N-methyl-D-aspartate receptor (NMDAR) antagonists have exposed their clinical effectiveness in a cluster of neurodegenerative diseases, such as epilepsy, Alzheimer’s disease, Parkinson’s disease, pain, and depression. Hence, GluN2B/NMDARs are considered to be a prospective target for the management of neurodegenerative diseases. Here, we have discussed the current results and significance of subunit selective GluN2B/NMDAR antagonists to pave the way for the establishment of new, safe, and economical drug candidates in the near future. By using summarized data of selective GluN2B/NMDAR antagonists, medicinal chemists are certainly a step closer to the goal of improving the therapeutic and side effect profile of selective antagonists. Outlined summary of designing strategies, synthetic schemes, and pharmacological evaluation studies reinvigorate efforts to identify, modify, and synthesize novel GluN2B/NMDAR antagonists for treating neurodegenerative diseases.

Keywords: GluN2B/NMDAR, design, synthesis, pharmacological studies, antagonists, diseases.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 09 March, 2021
Page: [822 - 862]
Pages: 41
DOI: 10.2174/1871527320666210309141627
Price: $65

Article Metrics

PDF: 256